---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078577"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:36:52.249794+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Liminatus Pharma provides IBA101 strategic update targeting PD-1/L1 patent cliff partnership opportunities

## Summary
- IBA101 is a CD47 mAb designed to avoid RBC/platelet binding, eliminating cytopenia that derailed Hu5F9 and lemzoparlimab.
- Preclinical data shows IBA101 + anti-PD-1 combination produces synergistic anti-tumor response with favorable safety.
- Company claims it is the only U.S.-based firm developing a CD47 blocker with a validated safety profile.
- PD-1/L1 inhibitors Keytruda (Merck) and Opdivo (BMS) face core patent expiry by 2028; others (Tecentriq, Imfinzi, Libtayo) by 2030.
- Strategy positions IBA101 as a patent-protected synergistic partner to extend PD-1/L1 franchise lifecycles.

## SEC filing metadata
- accession: 0001104659-25-078577
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465925078577/0001104659-25-078577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465925078577/tm2523534d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078577
- JSON: https://secwatch.observer/filing/0001104659-25-078577.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078577.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.